Acepodia
Alameda
About Acepodia
Acepodia is a clinical-stage biotechnology business that is using its proprietary Antibody-Cell Conjugation (ACC) platform technology to produce first-in-class cell treatments to solve gaps in cancer care. Acepodia employs this live-cell compatible chemistry to attach tumor-targeting antibodies directly to a variety of immune cell receptors, enhancing the lock between immune and cancer cells and generating highly specific, potent cell therapies without the need for genetic engineering. Acepodia is committed to immunotherapeutic strategies against oncology – expanding our research, clinical development, and manufacturing capabilities. Acepodia currently has a broad pipeline portfolio, each targeting a different type of cancer.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $256.0M
- Funding stage: Late Stage Venture
- Last round: Series D (Jun 2023)
- Website: acepodia.com
- Phone: (415) 366 7822
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/acepodia-85149 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.